Mometasone

證據等級: L5

預測適應症: 1 個

Mometasone: From Corticosteroid-Responsive Dermatologic/Allergic Conditions to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Mometasone is a corticosteroid conventionally used to treat inflammatory dermatologic and allergic conditions (specific original indication not recorded in this evidence pack). The TxGNN model predicts it may be effective for Primary Cutaneous T-Cell Lymphoma, but currently 0 clinical trials and only 2 case-report publications are available, and one of them actually reports treatment failure with mometasone in a related condition.

Quick Overview

Item	Content
Original Indication	Not recorded in evidence pack (no `original_indications` or Norway license text available); mometasone is generally classified as a corticosteroid
Predicted New Indication	Primary Cutaneous T-Cell Lymphoma
TxGNN Prediction Score	99.36%
Evidence Level	L5 (model prediction only — no direct supporting studies)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this drug in the evidence pack. Based on general pharmacological knowledge, mometasone is a corticosteroid with anti-inflammatory and immunosuppressive properties, commonly used for inflammatory skin and allergic/respiratory conditions. A plausible mechanistic rationale for its use in cutaneous T-cell lymphoma (CTCL) is that topical corticosteroids can suppress cutaneous lymphocytic infiltration and inflammation, which is part of standard supportive/adjunct management in early-stage mycosis fungoides (a form of CTCL).

However, the two literature items retrieved for this prediction do not provide direct positive support: one describes a case of cutaneous pseudolymphoma (a mimicker of CTCL, not CTCL itself) in which mometasone treatment was unsuccessful, and the other is a pediatric mycosis fungoides case report whose abstract does not mention mometasone at all. This means the model's high score is not currently corroborated by direct clinical evidence — the association appears to be driven by network/embedding similarity rather than documented efficacy.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40821495	2025	Case report	Proceedings (Baylor University Medical Center)	Cutaneous pseudolymphoma (a CTCL mimic) on the nose; mometasone and tacrolimus were both unsuccessful; case eventually treated with tapinarof
25442255	2015	Case report	Journal of Cutaneous Pathology	Pediatric (11-year-old) CD8+CD56+ mycosis fungoides (a primary CTCL subtype); abstract does not mention mometasone treatment

⚠️ Neither publication demonstrates efficacy of mometasone for primary cutaneous T-cell lymphoma; one explicitly documents treatment failure in a related but distinct diagnosis.

Norway Market Information

Mometasone is currently not marketed in Norway under this evidence pack (market_status: 未上市, 0 authorizations on file). No product license records are available.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA label warnings/contraindications and drug-drug interaction data are listed as data gaps (DG001, blocking severity) in the evidence pack meta section and must be resolved before any clinical safety assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score, there is no clinical trial evidence and the only two literature citations do not support — and in one case contradict — efficacy for this indication. Combined with missing MOA data and a blocking gap in TFDA safety/label information, this candidate does not yet meet the threshold for further evaluation.

To proceed, the following is needed:

Resolve DG001 (TFDA label warnings/contraindications) — currently blocking safety evaluation
Resolve DG002 (mechanism of action) via DrugBank to assess mechanistic plausibility for CTCL
Identify literature or preclinical studies specifically evaluating corticosteroids (mometasone or class) in primary cutaneous T-cell lymphoma/mycosis fungoides, rather than tangential case reports
Reassess whether the two retrieved case reports are genuinely relevant, given one shows treatment failure in a differential-diagnosis condition
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.